vs
Amarin Corp plc（AMRN）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
RE/MAX Holdings, Inc.的季度营收约是Amarin Corp plc的1.6倍（$71.1M vs $45.1M），RE/MAX Holdings, Inc.净利率更高（2.0% vs -23.3%，领先25.3%），Amarin Corp plc同比增速更快（7.0% vs -1.8%），过去两年RE/MAX Holdings, Inc.的营收复合增速更高（-4.7% vs -18.3%）
Amarin是一家1993年成立的爱裔美籍生物制药企业，总部分别设于爱尔兰都柏林与美国新泽西州布里奇沃特。该企业专注研发及销售心血管疾病治疗药物，已推出处方级Omega-3脂肪酸药物Vascepa（AMR-101）。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
AMRN vs RMAX — 直观对比
营收规模更大
RMAX
是对方的1.6倍
$45.1M
营收增速更快
AMRN
高出8.8%
-1.8%
净利率更高
RMAX
高出25.3%
-23.3%
两年增速更快
RMAX
近两年复合增速
-18.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $71.1M |
| 净利润 | $-10.5M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | 35.5% | 13.1% |
| 净利率 | -23.3% | 2.0% |
| 营收同比 | 7.0% | -1.8% |
| 净利润同比 | 33.0% | -75.2% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRNRMAX
| Q1 26 | $45.1M | — | ||
| Q4 25 | $49.2M | $71.1M | ||
| Q3 25 | $49.7M | $73.2M | ||
| Q2 25 | $72.7M | $72.8M | ||
| Q1 25 | $42.0M | $74.5M | ||
| Q4 24 | $62.3M | $72.5M | ||
| Q3 24 | $42.3M | $78.5M | ||
| Q2 24 | $67.5M | $78.5M |
净利润AMRNRMAX
| Q1 26 | $-10.5M | — | ||
| Q4 25 | $-1.2M | $1.4M | ||
| Q3 25 | $-7.7M | $4.0M | ||
| Q2 25 | $-14.1M | $4.7M | ||
| Q1 25 | $-15.7M | $-2.0M | ||
| Q4 24 | $-48.6M | $5.8M | ||
| Q3 24 | $-25.1M | $966.0K | ||
| Q2 24 | $1.5M | $3.7M |
毛利率AMRNRMAX
| Q1 26 | — | — | ||
| Q4 25 | 47.1% | — | ||
| Q3 25 | 44.7% | — | ||
| Q2 25 | 69.2% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | -15.4% | — | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 63.4% | — |
营业利润率AMRNRMAX
| Q1 26 | 35.5% | — | ||
| Q4 25 | -12.9% | 13.1% | ||
| Q3 25 | -22.4% | 25.0% | ||
| Q2 25 | -22.0% | 19.3% | ||
| Q1 25 | -39.9% | 7.2% | ||
| Q4 24 | -84.3% | 5.9% | ||
| Q3 24 | -59.5% | 19.4% | ||
| Q2 24 | -0.8% | 20.6% |
净利率AMRNRMAX
| Q1 26 | -23.3% | — | ||
| Q4 25 | -2.5% | 2.0% | ||
| Q3 25 | -15.6% | 5.4% | ||
| Q2 25 | -19.4% | 6.4% | ||
| Q1 25 | -37.4% | -2.6% | ||
| Q4 24 | -78.0% | 8.0% | ||
| Q3 24 | -59.4% | 1.2% | ||
| Q2 24 | 2.3% | 4.7% |
每股收益（稀释后）AMRNRMAX
| Q1 26 | — | — | ||
| Q4 25 | $0.00 | — | ||
| Q3 25 | $-0.02 | — | ||
| Q2 25 | $-0.03 | — | ||
| Q1 25 | $-0.04 | — | ||
| Q4 24 | $-0.12 | — | ||
| Q3 24 | $-0.06 | — | ||
| Q2 24 | $0.00 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $307.8M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | — | $452.4M |
| 总资产 | $645.8M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资AMRNRMAX
| Q1 26 | $307.8M | — | ||
| Q4 25 | $302.6M | $118.7M | ||
| Q3 25 | $286.6M | $107.5M | ||
| Q2 25 | $298.7M | $94.3M | ||
| Q1 25 | $281.8M | $89.1M | ||
| Q4 24 | $294.2M | $96.6M | ||
| Q3 24 | $305.7M | $83.8M | ||
| Q2 24 | $306.7M | $66.1M |
总债务AMRNRMAX
| Q1 26 | — | — | ||
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M |
股东权益AMRNRMAX
| Q1 26 | — | — | ||
| Q4 25 | $459.3M | $452.4M | ||
| Q3 25 | $458.9M | $448.1M | ||
| Q2 25 | $464.9M | $442.4M | ||
| Q1 25 | $473.7M | $433.5M | ||
| Q4 24 | $486.2M | $429.5M | ||
| Q3 24 | $531.4M | $423.1M | ||
| Q2 24 | $551.9M | $418.4M |
总资产AMRNRMAX
| Q1 26 | $645.8M | — | ||
| Q4 25 | $670.8M | $582.5M | ||
| Q3 25 | $659.8M | $582.2M | ||
| Q2 25 | $670.1M | $574.8M | ||
| Q1 25 | $655.7M | $571.4M | ||
| Q4 24 | $685.3M | $581.6M | ||
| Q3 24 | $750.6M | $578.6M | ||
| Q2 24 | $799.9M | $571.4M |
负债/权益比AMRNRMAX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $40.9M |
| 自由现金流经营现金流 - 资本支出 | — | $33.5M |
| 自由现金流率自由现金流/营收 | — | 47.1% |
| 资本支出强度资本支出/营收 | — | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | — | $56.8M |
8季度趋势，按日历期对齐
经营现金流AMRNRMAX
| Q1 26 | — | — | ||
| Q4 25 | $15.3M | $40.9M | ||
| Q3 25 | $-12.7M | $17.7M | ||
| Q2 25 | $16.6M | $4.6M | ||
| Q1 25 | $-12.5M | $5.7M | ||
| Q4 24 | $-13.3M | $59.7M | ||
| Q3 24 | $-2.4M | $17.6M | ||
| Q2 24 | $-2.7M | $15.9M |
自由现金流AMRNRMAX
| Q1 26 | — | — | ||
| Q4 25 | — | $33.5M | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $4.0M | ||
| Q4 24 | — | $53.0M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $14.0M |
自由现金流率AMRNRMAX
| Q1 26 | — | — | ||
| Q4 25 | — | 47.1% | ||
| Q3 25 | — | 22.4% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.3% | ||
| Q4 24 | — | 73.2% | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 17.8% |
资本支出强度AMRNRMAX
| Q1 26 | — | — | ||
| Q4 25 | — | 10.4% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.4% |
现金转化率AMRNRMAX
| Q1 26 | — | — | ||
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | -1.81× | 4.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
